M L McNeely1. 1. Department of Physical Therapy & Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada. mmcneely@ualberta.ca
In India, head and neck cancer (HNC) accounts for approximately 30 per cent of all cancers and is an important disease in terms of incidence and mortality in the region1. The primary risk factors associated with head and neck cancer include tobacco use, alcohol consumption, and infections such as human papillomavirus infection and Epstein-Barr virus2. Oral cancers, in particular, are more common in India, owing to the high prevalence of tobacco use and unique practices of betel quid and areca nut chewing3.The prognosis for HNC is dependent on the stage at diagnosis and the site of the tumour45. The five-year survival rates for early stage (I and II) range from 60 to 95 per cent4 and late stage (III and IV) range from 0 to 50 per cent5. Surgery remains a primary modality of therapy for early stage resectable tumours. For more advanced stage cancers, surgery is most often followed by radiotherapy. HNC is now more commonly treated with organ preserving neoadjuvant or concomitant chemoradiotherapy (CRT)2. The use of concomitant CRT has avoided many cosmetic and functional losses associated with surgery but commonly results in long-term effects such as loss of muscle mass, profound deconditioning and fatigue6.Exercise has emerged as a promising intervention in cancer prevention and control7. Several studies have examined physical activity and exercise behaviour in the cancer population. The percentage of cancer survivors who exercise regularly is shown to be as low as 20 per cent8. In a cohort study of HNC survivors, only 30.5 and 8.5 per cent were meeting public health guidelines for physical activity pre-treatment and after diagnosis, respectively9. These findings suggest that the impact of HNC treatment on activity level is significant and that the majority of HNC patients are not likely exercising at a sufficient level to provide health benefits9. Observational data from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial demonstrated a protective association between increased physical activity and HNC risk10. While the relationship between physical activity and HNC survival is not clear, the finding suggests a need for, and potential benefit from interventions to promote physical activity and exercise during and following HNC treatment.Research has demonstrated the safety, efficacy, and feasibility of physical activity and exercise interventions during and following cancer treatment11. There is now strong evidence in support of the benefits of exercise on body composition, cardiorespiratory fitness, muscular fitness, flexibility and quality of life for cancer survivors both during and following treatment. Speck et al11 performed a combined systematic review and meta-analysis examining the benefit of exercise interventions for health-related outcomes including quality of life. The review focused on two time points along the cancer continuum; during and following cancer treatment and included data from 82 controlled trials. In the meta-analysis, the pooled results showed a small to moderate positive effect from exercise interventions carried out during cancer treatment for outcomes such as functional capacity, muscular strength, functional quality of life, anxiety and self-esteem. While this review provides strong evidence in support of exercise as an intervention for cancerpatients and survivors, the evidence to date is largely from trials performed with breast cancer survivors (i.e. 83%). In the case of HNC, only a few exercise trials have been performed, and the need for empirical research on the relative safety and efficacy of exercise in this population is long overdue.Samuel and colleagues in this issue have performed a randomized controlled trial (RCT) including 48 HNC patients undergoing concomitant CRT12. The 24 HNC patients randomized to the intervention group followed a six-week supervised walking and active exercise training programme, while the 24 control patients only received advice to remain as physically active as possible over the course of treatment. The preliminary findings support the safety and efficacy of supervised exercise to improve functional capacity and quality of life (mental component score) among HNC patients undergoing CRT. The authors have demonstrated the use of standardized outcome measures in the study to document change over time. The use of the six-minute walk test, a low complexity test, is a strength of the study. Although maximal oxygen uptake (VO2max) is considered the gold standard measure of functional capacity, maximal testing is often not practical in the clinical settings. The six-minute walk test is a clinically feasible objective measure of functional capacity that avoids the need for expensive equipment and specialized training. As the authors acknowledge, a minimal clinically important difference (MCID) for the six-minute walk test in the range of 50 metres has been established in other disease populations. While the median improvement of 42 metres in the intervention group did not meet this MCID; the findings should be considered in light of the median decline of 96 metres seen in the control group12. As other studies have found, the benefit of exercise may be in the prevention and/or attenuation of declines in functional capacity commonly observed during anti-cancer treatment12. Importantly, both the supervised exercise protocol and standardized outcomes used in the study are feasible for implementation in the clinical setting.The strengths of this study include being the first RCT to examine the effect of exercise on functional capacity in patients with HNC undergoing CRT. As HNC and its treatment result in considerable impairment, patients often have very specific needs beyond those of most other individuals diagnosed with cancer.The authors have also addressed the limitations of their research study, namely factors associated with risk of bias such as lack of allocation concealment and blinding of outcome assessors12. Furthermore, this study would have been strengthened by the inclusion of other relevant outcomes. For example, as the intervention consisted of both walking and active exercise training, the collection of data on measures of musculoskeletal fitness, body composition and symptoms of fatigue would have allowed for a more comprehensive understanding of the effect of the exercise intervention on overall physical functioning. The lack of data on exercise adherence and factors affecting adherence are additional limitations of the study. As fatigue is a common and debilitating symptom during HNC treatment, onset of this symptom may have affected attendance at supervised sessions and impacted exercise performance. Alternatively, improvements in functional capacity may have mediated the fatigue response potentially allowing for better exercise adherence and performance13. Collection of this important data would be valuable to further understand the inter-relationship between exercise and fatigue12.In 2010, a round table was convened by the American College of Sports Medicine to review the evidence and provide guidelines for cancer survivors on physical activity7. The panel concluded that cancerpatients and survivors, even those undergoing intensive anti-cancer treatment protocols, should be advised to remain active. As nicely illustrated in this RCT12, despite undergoing CRT, these HNC patients were able to successfully participate in, and obtain benefit from a six-week supervised exercise intervention during treatment. As noted by Samuel et al, based on the positive findings of their study, future research directions include determining the optimal type and intensity of exercise for HNC patients.
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: Rebecca M Speck; Kerry S Courneya; Louise C Mâsse; Sue Duval; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2010-01-06 Impact factor: 4.442
Authors: Kerstin M Stenson; Ellen Maccracken; Rangesh Kunnavakkam; Ezra E W Cohen; Louis D Portugal; Victoria Villaflor; Tanguy Seiwert; Elizabeth Blair; Daniel J Haraf; Joseph K Salama; Everett E Vokes Journal: Head Neck Date: 2011-11-03 Impact factor: 3.147
Authors: Laura Q Rogers; Kerry S Courneya; K Thomas Robbins; James Malone; Alison Seiz; Lori Koch; Krishna Rao; Meenakshi Nagarkar Journal: Support Care Cancer Date: 2006-03-15 Impact factor: 3.603
Authors: Kerry S Courneya; Christopher M Sellar; Clare Stevinson; Margaret L McNeely; Carolyn J Peddle; Christine M Friedenreich; Keith Tankel; Sanraj Basi; Neil Chua; Alex Mazurek; Tony Reiman Journal: J Clin Oncol Date: 2009-08-17 Impact factor: 44.544
Authors: Joseph C Taylor; Jeffrey E Terrell; David L Ronis; Karen E Fowler; Carol Bishop; Michael T Lambert; Larry L Myers; Sonia A Duffy; Carol R Bradford; Douglas B Chepeha; Norman D Hogikyan; Mark E Prince; Theodoos N Teknos; Gregory T Wolf Journal: Arch Otolaryngol Head Neck Surg Date: 2004-06
Authors: Mia Hashibe; Paul Brennan; Shu-Chun Chuang; Stefania Boccia; Xavier Castellsague; Chu Chen; Maria Paula Curado; Luigino Dal Maso; Alexander W Daudt; Eleonora Fabianova; Leticia Fernandez; Victor Wünsch-Filho; Silvia Franceschi; Richard B Hayes; Rolando Herrero; Karl Kelsey; Sergio Koifman; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Juan J Lence; Dana Mates; Elena Matos; Ana Menezes; Michael D McClean; Joshua Muscat; Jose Eluf-Neto; Andrew F Olshan; Mark Purdue; Peter Rudnai; Stephen M Schwartz; Elaine Smith; Erich M Sturgis; Neonilia Szeszenia-Dabrowska; Renato Talamini; Qingyi Wei; Deborah M Winn; Oxana Shangina; Agnieszka Pilarska; Zuo-Feng Zhang; Gilles Ferro; Julien Berthiller; Paolo Boffetta Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: Rachita Gururaj; Stephen Rajan Samuel; K Vijaya Kumar; Anupama Hegde; P U Prakash Saxena; Ravishankar Nagaraja; Oxana Palesh Journal: Laryngoscope Investig Otolaryngol Date: 2021-10-29